CastleArk Alternatives’s AtriCure ATRC Stock Holding History

CastleArk Alternatives’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-145,966	Closed	-$10.2M	–	48
2021 Q3	$10.2M	Buy	+145,966	New	+$11.2M	0.39%	69

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

CastleArk Alternatives's ATRC Position: Q4 2021 in Review

CastleArk Alternatives sold out of AtriCure (ATRC) in Q4 2021, closing a stake of 145,966 shares — an estimated $10.2M sold.

CastleArk Alternatives first reported a position in ATRC in Q3 2021 and held it in 1 quarter. The position peaked at $10.2M in Q3 2021. 217 funds tracked by Wall St. Rank hold ATRC as of Q4 2021.

CastleArk Alternatives reported no remaining AtriCure position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 145,966 AtriCure shares in Q4 2021, an estimated $10.2M.
CastleArk Alternatives first reported a position in AtriCure in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's AtriCure position peaked at $10.2M in Q3 2021.
217 funds tracked by Wall St. Rank held AtriCure as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.